• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypoglycemia - Pipeline Review, H1 2017

    Hypoglycemia - Pipeline Review, H1 2017

    • Report Code ID: RW0001689439
    • Category Healthcare
    • No. of Pages 66
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H1 2017, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

    Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 5, 4, 1 and 1 respectively.

    Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
    - The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hypoglycemia - Overview
    Hypoglycemia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Hypoglycemia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hypoglycemia - Companies Involved in Therapeutics Development
    Eiger BioPharmaceuticals Inc
    Eli Lilly and Company
    Heptares Therapeutics Ltd
    Novartis AG
    Therakind Ltd
    USV Pvt Ltd
    Vectura Group Plc
    XERIS Pharmaceuticals Inc
    XOMA Corp
    Zealand Pharma AS
    Zucara Therapeutics Inc
    Hypoglycemia - Drug Profiles
    dasiglucagon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Hypoglycemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    exendin-(9-39) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glucagon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glucagon biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-3143753 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-3185643 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-900018 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pasireotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRL-2903 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    terbutaline sulphate MR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XOMA-129 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XOMA-358 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hypoglycemia - Dormant Projects
    Hypoglycemia - Discontinued Products
    Hypoglycemia - Product Development Milestones
    Featured News & Press Releases
    Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
    Dec 13, 2016: Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics
    Dec 12, 2016: Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia
    Nov 29, 2016: Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia
    Oct 17, 2016: Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency
    Sep 15, 2016: XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
    Sep 06, 2016: XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016
    Aug 11, 2016: Phase II results with dasiglucagon (ZP4207) support its potential for use in a ready-to-use rescue pen to treat severe hypoglycemia in diabetes
    Jun 13, 2016: Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
    May 10, 2016: Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery
    Apr 27, 2016: XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
    Apr 04, 2016: XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
    Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes
    Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism
    Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand’s stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hypoglycemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2017
    Hypoglycemia - Pipeline by Eli Lilly and Company, H1 2017
    Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H1 2017
    Hypoglycemia - Pipeline by Novartis AG, H1 2017
    Hypoglycemia - Pipeline by Therakind Ltd, H1 2017
    Hypoglycemia - Pipeline by USV Pvt Ltd, H1 2017
    Hypoglycemia - Pipeline by Vectura Group Plc, H1 2017
    Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H1 2017
    Hypoglycemia - Pipeline by XOMA Corp, H1 2017
    Hypoglycemia - Pipeline by Zealand Pharma AS, H1 2017
    Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H1 2017
    Hypoglycemia - Dormant Projects, H1 2017
    Hypoglycemia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hypoglycemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Eiger BioPharmaceuticals Inc
    Eli Lilly and Company
    Heptares Therapeutics Ltd
    Novartis AG
    Therakind Ltd
    USV Pvt Ltd
    Vectura Group Plc
    XERIS Pharmaceuticals Inc
    XOMA Corp
    Zealand Pharma AS
    Zucara Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//hypoglycemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hypoglycemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hypoglycemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments